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Selective degeneration of striatal neurons is a pathologic hallmark of Huntington disease (HD). The exact
mechanism(s) behind this specific neurodegeneration is still unknown. Expression studies of diseased
human post-mortem brain, as well as different mouse models exhibiting striatal degeneration, have demon-
strated changes in the expression of many important genes with a large proportion of changes being
observed in the striatal-enriched genes. These investigations have raised questions about how enrichment
of particular transcripts in the striatum can lead to its selective vulnerability to neurodegeneration.
Monitoring the expression changes of striatal-enriched genes during the course of the disease may be infor-
mative about their potential involvement in selective degeneration. In this study, we analyzed a Serial
Analysis of Gene Expression (SAGE) database (www.mouseatlas.org) and compared the mouse striatum
to 18 other brain regions to generate a novel list of striatal-enriched transcripts. These novel striatal-enriched
transcripts were subsequently evaluated for expression changes in the YAC128 mouse model of HD, and dif-
ferentially expressed transcripts were further examined in human post-mortem caudate samples. We ident-
ified transcripts with altered expression in YAC128 mice, which also showed consistent expression
changes in human post-mortem tissue. The identification of novel striatal-enriched genes with altered
expression in HD offers new avenues of study, leading towards a better understanding of specific pathways
involved in the selective degeneration of striatal neurons in HD.
INTRODUCTION
Huntington disease (HD) is an autosomal dominant neurode-
generative disorder caused by a CAG repeat expansion in
exon 1 of the HTT gene resulting in expression of mutant hun-
tingtin protein (HTT) with an expanded polyglutamine region.
The prevalence of HD is estimated to be almost 1 in 10 000 in
populations of European descent that is reduced approximately
10-fold in individuals of Asian or African ancestry. Patients
with HD develop symptoms of motor, cognitive and neuropsy-
chiatric disturbances that eventually lead to complete disabil-
ity and death approximately 18–25 years following the onset
of the disease.
An important hallmark of HD is the selective neuronal
degeneration in the caudate and putamen (together known as
the striatum), which occurs despite the ubiquitous expression
of mutant HTT throughout the brain and body of HD patients.
This selective degeneration can be characterized by early striatal
atrophy and neuronal dysfunction (1,2) as well as 90% loss of the
main population of striatal neurons, the GABAergic medium
spiny neurons (MSNs), by the late stages of the disease (1).
Other brain regions are also affected in HD including cortex,
globus pallidus, thalamus and hypothalamus (2,3). The severity
of striatal pathology is correlated with the degree of motor and
cognitive impairments (2,4), suggesting a central role for striatal
degeneration in HD symptomatology. However, the underlying
mechanism by which mutant HTT causes selective striatal
degeneration in HD is not well understood. Consequently, no
effective treatment or cure exists for HD.
The selective neuronal degeneration in HD has led to many
studies investigating the unique physiology of the striatum
compared with other brain regions. One such study focused
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on the expression of striatal-enriched genes (genes with higher
relative expression in the striatum compared with other brain
regions) in a mouse model of HD as well as in human post-
mortem brain (5). Interestingly, the product of these genes
has been associated with biological processes previously
implicated in HD (6). Therefore, although results from brain
global transcriptional analyses (7–10) have proven to be
insightful, we propose that the study of striatal-enriched
genes will more specifically contribute to our understanding
of the unique striatal physiology and its selective susceptibility
to degeneration in HD.
In this study, we analyzed the Serial Analysis of Gene
Expression (SAGE) database from the Mouse Atlas of Gene
Expression project (www.mouseatlas.org) (11) to compare the
relative abundance of transcripts in normal striatum to that in
18 other brain regions and thus to select for striatal-enriched
genes. This Mouse Atlas project includes spatially and tem-
porally restricted gene-expression profiles throughout murine
development in a total of 200 cells and tissues (11). SAGE is a
relatively unbiased method for large-scale gene expression pro-
filing as, unlike microarray methods, it does not require prior
knowledge of the genes expressed. Thus, it has the potential to
identify novel genes (12).
We generated a list of novel striatal-enriched genes which
included annotated transcripts not previously described as
striatal-enriched as well as unannotated transcripts expressed
specifically in the striatum. We analyzed the expression of the
candidate genes in the YAC128 mouse model of HD.
YAC128 mice express mutant HTT under its endogenous regu-
latory elements from a yeast artificial chromosome (YAC) trans-
gene. YAC128 mice exhibit progressive motor dysfunction,
cognitive impairment, impaired lifespan and progressive selec-
tive degeneration of specific neurons in the striatum thereby
recapitulating many aspects of the human disease (13,14). By
12 months, there are clear reductions in striatal volume, striatal
neuronal counts and striatal neuronal cross-sectional area in
these mice (13). Our recent studies have also identified
HD-related transcriptional changes in this mouse model at
12 and 24 months using microarrays (9) (Becanovic et al.,
submitted for publication). In the present study, we employed
quantitative real-time PCR as a more sensitive method to
detect changes in expression. We detected significant changes
in the relative abundance of 11% of our candidate
striatal-enriched transcripts in this mouse model at 12 months
of age. Subsequent analysis of orthologous transcripts
expression in human post-mortem caudate led to the identifi-
cation of the adaptor-related protein complex 1, sigma 1
subunit (Ap1s1) and Cd4 Antigen (Cd4) as genes whose
expression is significantly down-regulated in both YAC128
mouse striatum and caudate from HD patients.
We propose that the study of genes with enriched striatal
expression is a valid approach to identify candidate genes
involved in HD pathogenesis.
RESULTS
Identification of striatal-enriched SAGE tags
To identify novel striatal-enriched transcripts, we compared
the p84 SAGE library from striatum with libraries from 18
other brain regions in this database. A set of stringent selection
criteria (Fig. 1 and Materials and Methods) was developed to
establish a list of novel striatal-enriched genes. The algorithm
used to derive our candidate gene list is depicted in Figure 1.
To assess the validity of our SAGE analysis, we compiled a
list of previously reported striatal-enriched genes from two
publications, Desplat et al. (5) and de Chaldee et al. (15).
These two studies encompass the most comprehensive list of
known striatal-enriched transcripts identified to date.
Striatal enrichment/specificity of a given transcript was
determined based on its relative expression in striatum when
compared with 18 other brain tissues. First, a comparison
was made for adult [at 84 days postnatal (dpn)] brain libraries.
There were 32 216 (potential transcripts) unique tag sequences
in the 84 dpn striatum library, of which 6672 tag-sequences
were more abundant in the striatum than any other brain
library by at least one absolute tag count (raw count in
un-normalized library). This eliminated all tag-sequences
that were more abundant in any other brain region than in
striatum. Of these tags, 6044 were observed only once and
were exclusive to the striatum (i.e. one tag count in the stria-
tum and zero elsewhere). These ‘singletons’ may result from
sequencing and PCR errors or may well represent bona fide
low-abundance transcripts in the tissue (11). However, an
un-biased and careful analysis of such a large number of tag-
sequences and their corresponding transcripts were beyond the
targeted scope of our analysis, and thus they were excluded
from further consideration.
A P-value score (see Materials and Methods) representing
striatal enrichment for each tag relative to other brain
regions was calculated and 268 of 628 non-singleton tags
were significantly enriched. The abundance of the 268 tag-
sequences was also compared among all 18 brain libraries
over five developmental time points (pre-striatum, Theiler
stage 25, and at dpns 7, 35 and 84) using the mean tag
count. This tested whether or not a tag-sequence was preferen-
tially expressed in striatum throughout the development. This
criterion eliminated 81 tags from further consideration, but
preserved all previously documented striatal-enriched genes
among the 187 remaining tags.
Independent validation of striatal enrichment
SAGE measures absolute gene expression based on the
sequencing of mRNA-derived fragments. However, SAGE
libraries used in this project were constructed from a single
individual mouse for each developmental time point and this
must be considered when performing comparisons. SAGE
libraries constructed from different individual mice or mice
kept in different laboratories show correlations of only
0.66–0.78, or 0.5–0.58 for counts ,100, even when the
same inbred strain and tissues are used (12). Thus, to further
validate striatal enrichment of the selected tags, two sub-
sequent analyses were performed. First, tag-sequences repre-
senting known transcripts but lacking striatal-enriched
expression patterns in the Allen Institute for Brain Science
(AIBS) in situ hybridization images (n ¼ 82) were eliminated
from the list (Fig. 1).
At this stage, we gave consideration of the mapping of the
tag sequences to identified genomic loci. Twenty-three tags
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did not map to known genes. Fifteen of these tag-sequences
either mapped to the mitochondrial genome or could not
be definitely mapped to a single region in the mouse
genome (ambiguous hits) using Refseq, Mammalian Gene
Collection and Ensembl. Of the 90 remaining unambiguous
tag-sequences, 50 mapped to 34 previously reported
striatal-enriched genes (Fig. 1; Table 1) including 28/54
(52%) of the genes reported by Desplats et al. (5) and
18/28 (64%) of the genes reported by de Chaldee et al.
(15) (Table 1).
The second validation for striatal-enriched expression was
accomplished by qRT–PCR analysis. Expression analysis
was conducted for 40 tag-sequences that mapped to unambigu-
ous regions (a single sense position gene, an expressed
sequence tag (EST) or an AceView predicted transcript). Eigh-
teen of 40 transcripts (Ablim2, Actn1, Car11, Cd4, Cyld1,
Gpr83, Cacna2d3, Indo, Meis2, Ppp1r9a, Sh2d5, Smpd3,
Tbc1d8, Tmem158, predicted expansion of Gm705, tag down-
stream of Pde7b) were significantly enriched in wild-type
mouse striatum (n ¼ 3). Fifteen additional transcripts
(Ap1s1, Rgs4, Grm5, Gnao1, Gpr155, Kcnab1, Phactr1,
Plxnd1, Rgs7bp, C030013G03Rik, C030007101Rik,
BB360574, tag downstream Tmem16C) demonstrated a trend
toward higher striatal expression but did not reach statistical
significance. Most frequently, the expression of these
sequences was not significantly different between cortex and
striatum, but was enriched in striatum compared with the
rest of the brain. This may represent physiological similarities
between these two telencephalic brain regions. Five transcripts
(Me2, Rasl10db, Sytl5, Tmod1, tag downstream Neb1 gene)
were less abundant in striatum than one or more other brain
regions (one-way ANOVA, P  0.05). qRT–PCR results for
the predicted expansion of Gm705 (mapped to an un-annotated
region of the genome) (Fig. 2A) and Tmem158 (Fig. 2B) are
examples of significant striatal-enriched expression. Ap1s1
(Fig. 2C) expression demonstrates a trend towards striatal
enrichment, and Tmod1 (Fig. 2D) with lower expression in
striatum relative to other regions. The remaining qRT–PCR
results for validation of all candidate transcripts are in Sup-
plementary Material, Figure S2.
Based on the above validation, we identified 34 novel
striatal-enriched transcripts (Table 2).
Computational characterization and mapping of the novel
striatal-enriched SAGE tags
Tag-to-gene mapping of the 34 novel striatal-enriched SAGE
tags revealed that these tags represented 23 known genes,
two uncharacterized transcripts and two potential novel
splice variants of known genes (Table 2). Among the known
genes, cylindromatosis (turban tumor syndrome) gene
(Cyld1), adaptor protein complex AP-1 sigma 1 (Ap1s1), phos-
phatase and actin regulator 1 (Phactr1) and protein phospha-
tase 1, regulatory (inhibitor) subunit 9A (Ppp1r9a) were
Figure 1. Selection algorithm identified novel striatal-enriched transcripts. We defined ‘striatal-enriched’ transcripts as transcripts with dominant patterns of
expression in striatum compared to 18 other brain regions. Accordingly, selection criteria were designed to maximize detection of previously known
striatal-enriched genes. Enrichment of a SAGE tag in the striatum relative to other regions was determined by using a P-value score  13 at postnatal day
(dpn) 84 and mean ratio of 2.5 at all available time points. These two filtering steps reduced the number of tags to 187 consisting of tag-sequences
mapping to both known and unknown regions of the genome. Striatal enrichment seen in Allen Institute for Brain Science (AIBS) in situ database images
and quantitative real-time PCR were also used for further filtration of the SAGE tags. These selection criteria led to the identification of 34 novel striatal-enriched
tags which corresponded to 23 known genes, 4 uncharacterized genes and 2 novel splice variants of known genes.
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represented by two or more enriched SAGE tags implying that
two or more striatal-enriched splice variants exist for each of
these genes. There are two annotated splice-variants Cyld1,
and three for Phactr1. This is consistent with the number of
striatal-enriched SAGE tags selected for these genes. For
Ppp1r9a, there are three documented transcripts one of
which was not striatally enriched. For Ap1s1, we selected
two striatal-enriched tags, one of which corresponds to a
splice-variant for this gene that has not previously been
reported. Supplementary Material, Table S5 provides more
descriptive information regarding transcript titles and molecu-
lar functions of the 34 novel striatal-enriched candidate tran-
scripts obtained by our analysis.
Gene ontology (GO) provides standardized vocabulary
to describe genes and their corresponding products.
Using Expression Analysis Systematic Explorer (EASE)
Table 1. Thirty-four previously reported striatal-enriched genes obtained from our SAGE analysis
Tag Transcript P-value score Mean ratioa Corresponding tag ID Transcript reference
Known transcripts
1 Penk1 (A) 17.0 15.2 CTGCTTTGTGCTGTACA NM_001002927 Desplats et al., de Chaldee et al.
2 Penk1 (B) 15.6 61.2 AGAAGGGTGGGACGCCC NM_001002927 Desplats et al., de Chaldee et al.
3 Ppp1r1b (A) 17.0 14.3 TCCCTCCCTTAGTATCC NM_144828 Desplats et al., de Chaldee et al.
4 Ppp1r1b (B) 14.7 14.7 CTTTTCCGGGTCTCAGA NM_144828 Desplats et al., de Chaldee et al.
5 Rgs9 17.0 16.5 TGGGCCAGAAGATATCC NM_011268 Desplats et al., de Chaldee et al.
6 Rasd2 17.0 17.8 TTACATATGCCTTCCTC XM_204287 Desplats et al.
7 Arpp21 (A) 17.0 7.0 GGACGGCAGTTACCTCT NM_028755 Desplats et al., de Chaldee et al.
8 Arpp21 (B) 17.0 6.2 TTACTTGATCTCAGACC NM_028755 Desplats et al., de Chaldee et al.
9 Arpp21 (C) 16.9 25.9 GAGAGTGCTTTCTTTAA NM_028755 Desplats et al., de Chaldee et al.
10 Rxrg 17.0 26.6 GAAAGCAAACAAATGGA NM_009107 Desplats et al.
11 Gm705 17.0 15.3 TGCCTCTACTCCGTCAC AI836640 Desplats et al.
12 St8sia3 (A) 16.9 5.0 TGAATGAGGAATGTGAC NM_009182 de Chaldee et al.
13 St8sia3 (B) 14.2 5.5 GGGAAGGGCTCACGAAG NM_009182 de Chaldee et al.
14 Drd1a (A) 16.9 37.8 TGGATAGAACTGAAGGA NM_010076 Desplats et al.
15 Drd1a (B) 16.6 26.4 CTTGAAATGGCTTTCTG NM_010076 Desplats et al.
16 Adora2a 16.9 22.0 GACCCGAGCTGGATAGT NM_009630 Desplats et al.
17 Tmem90a (A) 16.8 39.7 TCTCCCTGTTACTGTGG NM_001033334 de Chaldee et al.
18 Tmem90a (B) 16.4 19.5 ATTTGGGGGACCTGGCC NM_001033334 de Chaldee et al.
19 Drd2 16.8 16.4 CACCAAACCAATAAAAC NM_010077 Desplats et al., de Chaldee et al.
20 Dgkb (A) 16.8 7.9 CACTCCCATAGGGTTTC NM_178681 Desplats et al.
21 Dgkb (B) 16.4 12.4 GGTAACACTAATACGTC NM_178681 Desplats et al.
22 Adcy5 16.8 11.9 GAACTCAAGGGTCTGCT XM_993156 Desplats et al., de Chaldee et al.
23 Gng7 16.8 12.7 GCACTTTCCATTTCCGT NM_010319 Desplats et al., de Chaldee et al.
24 Tesc 16.8 4.5 GAGACCATCGCCCTCTG NM_021344 Desplats et al., de Chaldee et al.
25 Scn4b 16.6 14.7 CCCAGCGCTTGCGTCTA NM_001013390 Desplats et al., de Chaldee et al.
26 Tac1 16.6 10.9 TTTCCTGTTTCGTGACT NM_009311 Desplats et al., de Chaldee et al.
27 pde10a (A) 16.4 7.2 AAATATATTTAGAAATG NM_011866 Desplats et al.
28 pde10a (B) 16.3 7.6 TCAAAGAATTAAAACAC NM_011866 Desplats et al.
29 pde10a (C) 15.9 31.0 TATGCACAAGCACACAG NM_011866 Desplats et al.
30 pde10a (D) 14.5 41.9 TTCATTTACTGTACAAA NM_011866 Desplats et al.
31 Gpr88 16.3 7.2 TCTGTTGAAGATGGAAT NM_022427 Desplats et al., de Chaldee et al.
32 pde1b 16.1 4.6 CTCTTGGTCTCCCAGGC NM_053202 Desplats et al., de Chaldee et al.
33 Rap1gap 15.9 2.7 TATGTCAGTAAGGGTTG XM_989545 Desplats et al., de Chaldee et al.
34 Spock3 15.8 5.0 TTAATTAATTGTGTAGA NM_001040159 de Chaldee et al.
35 Rasgrp2 15.7 11.6 CATTGAGAAGAGGGCCA NM_011242 Desplats et al.
36 Cpne5 (A) 15.5 4.7 ACTTCATTGGGGAGTTC NM_153166 Desplats et al.
37 Cpne5 (B) 15.0 6.0 GTGATAGTGATGTTTTG NM_153166 Desplats et al.
38 Pcp4l1 15.4 5.9 TTTAATAATGATGACAA XM_992882 de Chaldee et al.
39 Bcl11b 15.3 6.9 TGTCTGCCATTTCATTT NM_138576 Desplats et al.
40 Gnal (A) 15.0 7.5 CATAAAACCTGAGCTCA NM_177137 Desplats et al.
41 Gnal (B) 13.5 3.6 TGCCTGGCACATTTAGA NM_177137 Desplats et al.
42 Arpp19 14.8 3.2 ACTTTCAGTGGCCTTGT NM_021548 Desplats et al.
43 Ppp3ca 13.6 2.5 CCCTCTGACGCCAACCT NM_000944 Desplats et al., de Chaldee et al.
Novel splice-variants of known transcripts (AceView prediction available)
45 Adcy5.aSep07 17.0 12.1 GAAATTGAAAAGTCTAT N/A Desplats et al., de Chaldee et al.
46 Dgkb.aSep07 16.6 5.2 TGTGTATCGTGTGTATT N/A Desplats et al.
47 FoxP1.aSep07 16.1 3.7 AGCGCATTCTTAAATGC N/A Desplats et al.
48 Adcy5.aSep07 14.6 18.9 GAGGCTCCTCCCCACTC N/A Desplats et al., de Chaldee et al.
49 Strn.aSep07 13.4 4.1 TCCACTCTCCCTGCTTT N/A Desplats et al.
50 Arpp21.dSep07 13.0 8.4 TGCTGTTTACCTATTTA N/A Desplats et al., de Chaldee et al.
Using selection criteria described in Figure 1, 50 SAGE tags corresponded to 34 previously reported striatal genes. More than one SAGE tag may correspond to a
gene, representing its different splice variants. Genes published in Desplats et al. (5) and de Chaldee et al. (15) were used as points of reference.
P-value score indicates relative enrichment of the SAGE tag in the striatum at 3 months.
aMean ratio indicates relative enrichment of the SAGE tag in the striatum through five developmental time points.
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(http://david.abcc.ncifcrf.gov/), which provides statistical
methods for discovering enriched biological themes within
gene lists, we identified a wide range of classification through-
out the list of candidate genes but no specific GO classes were
over-represented in our novel striatal genes (data not shown).
The uncharacterized sequences to which our enriched tags
mapped were identified as Riken transcripts C030013G03Rik
and C030007I01Rik, an EST (BB360574), and also a
genomic sequence that may contain a novel transcriptional
unit (Table 2, tag no. 29). Tag-sequence no. 29 corresponds
to a novel transcript on the negative strand of Chromosome
19 and may represent expansion of gene Gm705. There are
no previously reported expression data for this region. These
results further indicate that our approach was successful in
the identification of novel markers of striatal expression
using SAGE.
SAGE is outstanding for detecting putative new splice var-
iants. This may include novel internal exons as well as novel
alternative 30 untranslated regions (UTRs) (12). As SAGE tags
derive from the 30 most anchoring enzyme site in a transcript,
many SAGE tags are expected to be derived from the 30-UTR
which is not consistently included in gene predictions. Two of
the novel striatal-enriched tag-sequences mapped to regions
downstream of transmembrane protein 16C (Tmem16C) and
phosphodiesterase 7b (Pde7b). AceView prediction (16) of
alternate splicing exists (Table 2). Both of these predictions
have demonstrated homology to the human mRNA of the cor-
responding genes. Similarly, in the list of the previously
reported striatal-enriched transcripts, mapping of SAGE tags
to AceView predictions led to identification of potential
novel splice-variants for previously reported striatal-enriched
genes such as adenylate cyclase 5 (Adcy5), diacylglycerol
kinase (Dgkb), forkhead box P1 (FoxP1), Striatin (Strn) and
cyclic AMP-regulated phosphoprotein, 21 (Arpp21) (Table 1).
Analysis of the candidate transcripts in the YAC128 mouse
model of HD
We predicted that transcripts enriched in the striatum are rel-
evant to the selective degeneration of this brain region in HD.
Thus, expression levels of all 34 novel striatal-enriched tran-
scripts were tested in 12-month-old YAC128 and wild-type
Figure 2. Examples of qRT–PCR results validating SAGE data. qRT–PCR was used for validation of 40 novel striatal-enriched transcripts obtained from SAGE
and AIBS analysis. qRT–PCR experiments for these transcripts revealed three groups of candidate transcripts: (i) transcripts whose expression was shown to be
significantly higher in the striatum; (ii) transcripts that show a trend towards striatal enrichment and (iii) transcripts that showed lower expression levels in the
striatum compared with at least one other tissue. A cross comparison between the expression levels in striatum, cortex, hippocampus, cerebellum, liver and
muscle using qRT–PCR revealed Gm705 expansion, a previously unknown striatal-enriched transcript (A), and Tmem158, a transcript not previously known
to be striatal-enriched (B) were significantly higher in the striatum; Ap1s1, a transcript selected by SAGE showed a trend towards striatal enrichment (C);
for transcript Trom1, striatal-enrichment was not validated using qRT–PCR (D). Overall, out of 40 transcripts, 45% showed a significantly higher level in stria-
tum, 37% showed a trend towards striatal enrichment and 17% showed lower levels of expression in striatum than at least one other tissue. Error bars represent
SEM. Significant differences were determined by a one-way ANOVA analysis using a threshold value of P, 0.05. The qRT–PCR results for rest of the candi-
date transcripts are in Supplementary Material, Figure S2.
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mice using qRT–PCR. Through this analysis, we found that
three genes exhibited a significant change in their mRNA
expression level. These included Cd4 antigen (P ¼ 0.015, n ¼
10 WT, 8 YAC128) and Ap1s1 (P ¼ 0.003, n ¼ 9 WT, 7
YAC128) that were down-regulated in the striatum of
YAC128 mice (Fig. 3A and B, respectively) and indoleamine-
pyrrole 2,3 dioxygenase (Indo) (P ¼ 0.05, n ¼ 10 WT, 8
YAC128) that was up-regulated in YAC128 striatum (Fig. 3C).
We further examined the expression of these three genes in
YAC128 mice at 3 months of age. Only Indo mRNA was sig-
nificantly up-regulated at this time point (P ¼ 0.039, n ¼ 7
WT, 5 YAC128) (Fig. 3C). Among a selected group of pre-
viously reported striatal-enriched genes (Ppp1rb1, Penk1,
Tac1, Gnal, Pcp4l, Spock3, St8sia3), we showed a significant
down-regulation of Ppp1rb transcripts (P ¼ 0.029, n ¼ 11
WT, 7 YAC128) (Fig. 3D) which was consistent with
reduction in Ppp1rb1 encoded protein (DARPP-32) in
YAC128 mice (17). We additionally identified, for the first
time in YAC128 mice, a significant down-regulation in Gnal
(P ¼ 0.02, n ¼ 10 WT, 7 YAC128) (Fig. 3E), consistent
with the known expression change in human HD putamen
(18). The expression level of these transcripts was further
tested in 12-month YAC18 transgenic mice over-expressing
normal human HTT. The results of these experiments
showed no expression change of these genes between
YAC18 and wild-type striatum, but demonstrate a significant
expression difference between YAC18 and YAC128 striatum.
These results suggest that changes in Ap1s1, Cd4 and Indo are
not due huntingtin dosage difference, but are likely to be a
result of the expression of mutant huntingtin. The data are
shown in Supplementary Material, Figure S1.
Overall, having examined all 34 candidate striatal-enriched
transcripts at 12 months, we identified three genes (containing
four striatal-enriched transcripts) whose levels of mRNA
expression were significantly changed in the striatum of
YAC128 mouse model of HD. This indicated that 11% of the
novel striatal-enriched transcripts selected through our SAGE
analysis showed significantly altered expression in this HD model.
Table 2. Final list of novel striatal-enriched transcripts obtained using SAGE
Tag Transcript P-value score Mean ratioa Corresponding tag ID
Known transcripts
1 Tmem158 17.0 6.3 GCCTGGTGGGCGTTTCT NM_001002267
2 Gnao1 16.8 2.6 TTGGGATGTTTGTGCTG NM_010308
3 Phactr1 (A) 16.8 4.1 TAAATCCGAACTGCCTT NM_198419
4 Phactr1 (B) 14.9 14.7 CGTTCCGACTCGCTGGT NM_198419
5 Phactr1 (C) 13.0 25.2 GGCCTTCCGGAAATAAG NM_198419
6 Meis2 16.6 4.9 TTAGATATTCTATGTGT NM_131896
7 Ap1s1 (A) 16.5 2.5 GGCCAAGTGGCTGCCTT NM_007457
8 Ap1s1 (B) 13.5 4.8 TGCCCTGTATGGCTGTA NM_007457
9 Kcnab1 16.5 5.2 GTTAAGTTCTAAATCTT NM_010597
10 Car11 16.0 3.5 TGGACGGTGGTCCTCAC NM_009800
11 Gpr155 16.0 2.8 TTTCTCAATAAAATACC XM_130346
12 Indo 15.9 86.8 ACTTTCCTAAGGAGTGT NM_008324
13 Rgs4 15.8 6.6 AACTGCAAAGCCCTCTT NM_009062
14 Actn1 15.8 2.6 GCTTCTCATTTTTCAGT NM_134156
15 Cacna2d3 15.7 3.2 GAAACCAATTTAAAACT NM_009785
16 Ablim2 15.4 3.5 GTCCCTTGTATAGCAAG NM_177678
17 Sh2d5 15.2 2.7 GCTCTGTGTCTATGCAG XM_357399
18 Plxnd1 14.9 2.7 GGCAGTGCCCATTGCCC XM_232283
19 Cyld (A) 14.9 4.3 TACTCTTTCTGTATCAT NM_173369
20 Cyld (B) 13.0 25.2 GATGCCAGGTTGCTAAA NM_173369
21 Ppp1r9a (A) 14.9 3.1 CAGTTACAGAAGCAGAG NM_017650
22 Ppp1r9a (B) 14.4 2.5 AAATAACAATTGGCCAG NM_181595
23 Grm5 14.5 4.3 TTGCCAATCAATACTGG XM_987218
24 Tbc1d8 14.2 5.2 CCTTTAATGTTTGTCCT NM_018775
25 Rgs7bp 14.2 2.9 CAAATGGACTAACTGAC NM_029879
26 Smpd3 13.9 4.6 TGCCACACTGTAGCACC NM_021491
27 Gpr83 13.6 5.7 ACCAGACAGGACCCATT NM_010287
28 Cd4 13.0 63.0 CTGGGGTCCTTTATGGA NM_013488
Unknown transcripts
29 Predicted extension of Gm705 14.8 21.7 TTCATCCCTCGCCCCCT N/A
30 C030007I01Rik cDNA 13.9 7.4 AGCTAACATAATGGGAC AK021055
31 C030013G03Rik cDNA 13.0 12.6 TTAGAAAGCAGTATTCC AK021075
32 N/A 13.0 6.3 GATTGTGACTATTTGAA BB360574
Novel splice-variants of known transcripts (based on AceView prediction)
33 Tmem16c.bSep07-unspliced 16.5 8.9 ATGAGATTCAACTTGAA N/A
34 Pde7b.bSep07 13.3 6.8 TCTATCCAGATGAACAT N/A
Through subsequent steps of filtration, 34 novel striatal-enriched transcripts were identified and mapped to 28 transcripts representing 23 known genes not
previously reported as striatal-enriched, 4 unknown transcripts and 2 novel splice-variants of known genes. Genes Phactr1, Ap1s1, Cyld, Ppp1r9a are represented
by more than one SAGE tag corresponding to their different splice variants.
P-value score indicates relative enrichment of the SAGE tag in the striatum at 3 months.
aMean ratio indicates relative enrichment of the SAGE tag in the striatum through five developmental time points.
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Figure 3. Five striatal-enriched genes respond to pathogenesis in the YAC128 mouse model of HD. Relative quantification of the mRNA levels of 34 novel
striatal-enriched transcripts in the striatum of 12-month-old YAC128 mice revealed the greatest mRNA changes for Ap1s1 (A) Cd4 (B) and Indo (C). These
transcripts were also tested at 3 months and only Indo mRNA expression exhibited a significant up-regulation at both 12 months and 3 months of age (C).
As expected, well-known striatal transcripts, Ppp1r1b and Gnal showed significant changes at 12 months (D and E). Tmem158 is an example of a
striatal-enriched gene with no alteration in expression level in the YAC128 mice (F). Error bars represent SEM. Significant differences were determined by
student’s t-test (unpaired; two-tailed) using a threshold value of P , 0.05.
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Analysis of mouse striatal gene expression changes in the
human HD caudate
To assess the relevance of the gene expression changes we
observed in the YAC128 mouse model of HD, we assayed
the expression of the differentially regulated genes in
caudate from HD patients and age-matched controls. Initially,
PPP1R1B (DARPP32 mRNA) expression level was measured.
This analysis was based on PPP1R1B previously reported
altered expression levels in human HD caudate and in different
mouse models of HD such as YAC128, fragment protein
models and knock-in models (5,9,10,19,20). These results
were reproduced in our qRT–PCR analyses of human post-
mortem caudate samples where PPP1R1B mRNA levels
were significantly reduced in HD compared with controls
(Fig. 4A). qRT–PCR was also performed for human orthologs
of Cd4, Ap1s1 and Indo. Human CD4 mRNA expression level
was significantly increased in human HD caudate indicating an
expression change opposite to what was observed in YAC128
striatum (Fig. 4B). Finally, consistent with the mouse data in
YAC128, human AP1S1 mRNA was shown, for the first
time, to be significantly reduced in human post-mortem HD
caudate (Fig. 4C). Despite being significantly enriched in
mouse striatum, human INDO transcript has unexpectedly
low abundance in human HD and control post-mortem
tissues to date, and has not been detected in our qRT–PCR
experiment. As an example of an unknown striatal-enriched
transcript with un-altered levels of expression in the
YAC128 mice, human ortholog of Gm705 transcript also
exhibited no transcriptional change in human HD samples.
DISCUSSION
This project identified a novel set of striatal-enriched tran-
scripts from an existing SAGE database, compared the
expression levels of these transcripts in the striatum of wild-
type and YAC128 transgenic mice, and further evaluated
those transcripts with altered expression in caudate samples
from post-mortem HD and control brain.
The transcripts selected through our SAGE analysis are
novel in two ways. (i) They have not been previously
described as striatal-enriched by other studies. (ii) They are
novel transcripts that were never discovered before. In either
case, previous studies have failed to detect them using other
techniques. SAGE allows the detection of tissue-specific low-
abundance transcripts which normally remain undetectable
using other techniques. SAGE also allows for the discovery
of novel transcripts, without a priori selection bias, while
other techniques such as microarrays lack this advantage.
Finally, the digital nature of SAGE tags makes them easy to
handle in computational analyses. In our study, 19 brain
regions are easily compared. The high efficiency of this
screen suggests that the MouseAtlas SAGE library database
is a powerful resource to identify tissue-specific transcripts.
Confirmation of previously reported striatal-enriched
genes
Although the goal of this project was to identify novel
striatal-enriched genes from an existing SAGE database
using a defined selection algorithm, we also assessed the selec-
tion of previously reported striatal-enriched genes at each
selection step to ensure the validity of our selection process.
Accordingly, while identifying novel striatal-enriched tran-
scripts, we were also able to detect a large proportion of the
striatal-enriched genes previously reported by Desplats et al.
(5) and de Chaldee et al. (15). We considered four main
reasons why not all of the previously reported genes met our
selection criteria:
(i) Our initial selection criteria required striatal-enriched
SAGE tags to be more abundant in the striatum than
other brain regions at dpn 84. As an example, the pre-
viously reported striatal-enriched transcript retinoic acid
receptor beta (Rarb) is highly expressed in striatum at
dpn 7 and dpn 37, but not at dpn 84. Therefore, this tran-
script and other similar transcripts that are transiently
enriched during striatal development are absent from
our striatal-enriched candidate list.
(ii) We compared expression data for 18 different brain
regions in this study and selected for SAGE tags that
had higher counts in the striatum than all 18 other brain
regions. Therefore, SAGE tags that manifest higher or
equal abundance in at least one other brain region were
eliminated. The hippocalcin (Hpca) SAGE tag, which
was highly abundant in the striatum, showed a higher
expression in CA1 and the neuronal guanine nucleotide
exchange factor (nGEF) SAGE tag which was more
abundant in visual cortex than in the striatum. These
genes and other previously reported striatal-enriched
genes were found to be highly expressed in the striatum,
but were expressed at higher levels in at least one other
brain region (e.g. synaptoporin) and based on our selec-
tion criteria, these genes are not considered
striatal-enriched in this analysis.
(iii) Low abundance transcripts may not be detected by this
specific SAGE analysis or may be at the singleton
level, which were excluded based on our selection cri-
teria. The SAGE tag for Htr6 gene (5-hydroxytryptamine
(serotonin) receptor 6) was excluded as a singleton.
(iv) Transcripts lacking the appropriate anchoring enzyme
site (e.g. NlaIII) will never appear in SAGE libraries as
no tag for these genes will be extracted (12). Similarly,
since SAGE relies on a polyadenylated tail for tag extrac-
tion, transcripts that are not polyadenylated will be
absent. Dopamine receptor 3 (Drd3) fails to have a
valid SAGE tag since its annotated transcript lacks a
poly-A tail. Therefore, despite being abundant in the
striatum, many previously reported striatal-enriched tran-
scripts were excluded from our candidate gene list due to
our specific selection criteria. Table 3 summarizes why
some documented striatal-enriched genes were excluded
by our criteria.
In selecting our list of candidate striatal-enriched genes, we
employed statistical filtration and in situ hybridization images
from the AIBS database. The use of AIBS database was ben-
eficial since it provided a more clear understanding of patterns
of expression of annotated transcripts. The estimated corre-
lation rate between SAGE and AIBS for known candidate
transcripts was 50% in our analysis. In a recent cDNA
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microarray study by Ghate et al. (21), the majority of their
novel striatal genes did not demonstrate clear striatal enrich-
ment in their in situ images in AIBS leading to questions
regarding the sensitivity of this resource. Overall, the semi-
quantitative and spatially restricted expression data provided
by in situ images was complementary to our study.
However, AIBS data in isolation are not a pragmatic source
for evaluating un-annotated transcripts.
Quantitative RT–PCR was used as another means to further
validate selection of our candidate gene list. Unlike the Mouse
Atlas of Gene Expression and AIBS data sets, multiple
animals were tested, resulting in a more robust analysis of
transcript expression patterns within the brain. Moreover, rela-
tive expression of all transcripts, including unknown tran-
scribed regions, was accessible for analysis using this
technique. Using qRT–PCR analysis, 18 transcripts from
our candidate list (45%) were significantly enriched in stria-
tum, and 15 transcripts (37%) showed a robust trend towards
striatal enrichment. In a previous study using qRT–PCR
analysis of mouse genes identified by SAGE, a correlation
of 0.64 between the two methods was found, but this study
only examined tags with counts greater than 45 (22). The
lower correlation in our analysis could be due to the lower
abundance of tags assessed (only required to be .1 count)
with the majority of our candidate transcripts expressed at
less than 45 counts. Similar reasoning could be used to
explain the 7 out of 40 (17%) transcripts that were less abun-
dant in striatum than at least one other tissue using qRT–PCR.
These data indicate that more abundant transcripts are more
likely to be validated using techniques such as qRT–PCR.
Identification and characterization of novel
striatal-enriched transcripts
Computational analysis of our novel candidate list of
striatal-enriched SAGE tags revealed 26 known genes, 4
uncharacterized transcripts and 2 putative novel splice variants
of previously annotated genes (Table 2). Trans-membrane
protein 158 (Tmem158), also known as Ras-induced senes-
cence 1, had the highest P-value score and was validated by
qRT–PCR (Fig. 2B). Tmem158 was previously implicated in
cancer (23) and can elicit new mechanisms in striatal physi-
ology. The transcript in Table 2 with the highest mean ratio
was indoleamine-pyrrole 2,3 dioxygenase (Indo), a gene
involved in tryptophan metabolism (Supplementary Material,
Fig. S2). Indo is striatally enriched throughout striatal devel-
opment and this expression pattern was validated using
qRT–PCR (data for other time points not shown). Similarly,
three variants of the phosphatase and actin regulator 1
(Phactr1) were selected as striatal-enriched transcripts.
Phactr1 has been found to inhibit protein phosphatase 1
(PP1) activity and also known to bind to actin. Phactr1 is
thought to dictate PP1 subcellular localization and in some
cases serve to potentiate PP1 toward select substrate at those
sites (24). A recent study by Shao et al. (25) demonstrated
that phosphorylation of an actin-binding factor protein profilin
regulates polyglutamine aggregation. Although we found no
difference in the level of Phactr1 in WT versus YAC128
animals, future investigation is required to determine the
role of Phactr1 in phosphorylation of actin cytoskeleton
components and how striatal-enrichment of this gene may
lead to striatal vulnerability to neurodegeneration. Cyld is
another interesting striatal-enriched candidate gene whose
Figure 4. Alteration in expression levels of striatal-enriched transcripts in
postmortem caudate of HD subjects. Transcripts that were differentially
expressed in the YAC128 mouse model of HD were tested in human
postmortem caudate samples from HD patients and age-matched controls.
PPP1R1B (A) and AP1S1 (C) showed significant down-regulation in HD
subjects compared with controls, similar to expression changes observed in
the YAC128 mouse model. CD4 (B) was significantly up-regulated in HD
subjects compared with controls, opposite to the change observed in the
YAC128 mouse model. Error bars represent SEM. Significant differences
were determined by student’s t-test (unpaired; two-tailed) using a threshold
value of P , 0.05.
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two different variants were selected through our analysis.
SAGE analysis, Allen Brain Atlas and qRT–PCR results all
indicate highly enriched patterns of expression in the striatum.
The deubiquitinating enzyme CYLD is a tumor suppressor
protein known to repress the NF-kB activation pathway (26).
The activation of this pathway is known to have anti-apoptotic
role and may play a role in response to injury in the CNS. We
have not observed any significant difference in Cyld expression
in YAC128 versus wild-type animals. However, Cyld remains
an important candidate for future studies of striatal-enriched
proteins. Computational analysis also led to the selection of
four unknown striatal-enriched transcripts one of which
(tag no. 29 in Table 2) maps to an un-annotated region of the
chromosome 19 genomic sequence. The striatal enrichment of
this transcribed region has also been shown in our study using
qRT–PCR (Fig. 2A). This novel striatal-enriched tag-sequence
may represent an alternative splice variant of the transcriptional
unit which also encompasses the SAGE tag located in a highly
conserved striatal-enriched gene Gm705 [described as a
striatal-enriched EST AI836640 in Desplats et al. (5)] also
selected in our analysis (Table 1, tag no. 11).
Altered expression levels of candidate striatal-enriched
genes in the YAC128 mouse model of HD and human
post-mortem HD brain
Next, we investigated the expression levels of the candidate
novel striatal-enriched transcripts selected by our analysis in
both the YAC128 mouse model of HD and in human post-
mortem HD caudate. Selective striatal degeneration in the
YAC128 mice manifests as striatal atrophy beginning at 9
months progressing to significant neuronal loss at 12 months
of age (13). Twelve-month-old YAC128 mice also have pro-
found motor deficits and show clear patterns of cognitive dys-
function appearing as decreased pre-pulse inhibition and
habituation to acoustic startle (14).
Based on the presence of striatal neuropathology, motor
dysfunction and cognitive phenotypes at 12 months in
YAC128 mice, striatal transcription was tested at this time
point. In addition to having the advantage of a mouse model
with an age-dependent selective striatal neurodegeneration,
the YAC128 model provided the advantage of testing tran-
scriptional changes induced by mutant HTT expressed from
the normal genomic context of the full-length human mutant
gene. Recently, it has been shown that prevention of
caspase-6-mediated cleavage of the full-length mutant HTT
protein in vivo can rescue the progressive HD phenotype of
the YAC128 model (27). This suggests that specific fragments
resulting from caspase-6 proteolysis of the full-length protein,
and not just any N-terminal fragments, are necessary for
pathogenesis in HD. Moreover, unlike N-terminal mouse
models where widespread mutant HTT aggregates rapidly
accumulate in the nucleus and massive transcriptional
changes have been demonstrated (5,6,10), the slower pro-
gression and more modest transcriptional changes seen in
YAC128 mice expressing the full-length mutant HTT
protein allow investigation of these changes throughout the
time-course of pathology. Comparing gene expression results
between the YAC128 model and N-terminal fragment
models again demonstrates that increased HTT protein
length reduces the number of polyglutamine-induced gene
expression changes (7).
One of the three novel striatal-enriched genes with altered
mRNA expression in YAC128 mice was Cd4. The Cd4
antigen is a membrane glycoprotein of T lymphocytes that inter-
acts with major histocompatibility class II (MHC II) antigens
and is also a receptor for the human immunodeficiency virus
(HIV). The gene is known to be expressed highly in thymus
and spleen but also lower levels are found in microglia in the
brain (28). Transgenic mice expressing the human CD4 gene
showed no evidence of neuronal damage until their brain was
activated by peripheral immune challenges which led to neuro-
degeneration in these mice (10). In post-mortem brain tissues
from AIDS patients with opportunistic infections, but without
typical HIV encephalitis, human CD4 expression correlated
with neurodegeneration (10). Our finding that Cd4 is a
striatal-enriched gene may explain the susceptibility of the stria-
tum to neuroinflammation observed in HD (29) and may provide
mechanistic insight into selective striatal degeneration in HD.
We demonstrate that CD4 transcript expression is significantly
up-regulated in human HD caudate samples compared with con-
trols, implying that there is altered immune activation in the
striatum of HD patients. However, the observed discrepancy
in Cd4 expression change between human postmortem
caudate and YAC128 striatum raises interesting questions
regarding the regulation of this transcript in postmortem
human brain versus mouse brain and its potential link to
disease progression in mouse and human. Further investigation
is required to first understand which brain cell types in the stria-
tum of YAC128 and patients express Cd4 (i.e. glial cells versus
MSNs) and to subsequently explain the role of Cd4 expression
in the context of neurodegeneration in HD.
Indo, another gene with altered mRNA expression levels in
the YAC128 mouse model, is a tryptophan-catabolizing
enzyme which initiates the first and rate limiting step of the
kynurenine pathway. In the brain, Indo can be induced in
microglia by interferon-g-producing T helper (Th) 1 cells.
Indo is thought to initiate a negative feedback loop which
decreases neuroinflammation in an animal model of multiple
sclerosis (MS) (30–32). On the other hand, induction of
Table 3. Some genes from Desplats et al. and de Chaldee et al. were not
selected through our SAGE analysis
Striatal-enriched genes not selected
using SAGE
Potential explanation
Rarb, Anap5, Nbr1 Gene is striatally enriched at a
developmental stage other than
adult
B3gh1, Klf9, Oprd1, Drrf, Synpr,
Foxp2, Hpca, Ngef, Baiap2, Nts,
Zfp503, Ppp1r16b
More abundant in at least one other
brain library (after normalizing)
Htr6, Chst15, Oprm1 Transcripts detected in the SAGE
library as singletons
Actn2, Efna4, Osbpl8 More abundant in at least one other
library in the form of singletons
Htr4, Drd3, Oprk1, Kcnip2 No valid SAGE tag for the
annotated transcript
Each gene is allocated under the category which potentially explains why the
gene did not get selected by SAGE.
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Indo activates the, kynurenine pathway leading to production
of neurotoxic metabolites such as 3 hydroxy-Kyurenine and
quinolinic acid known to be involved in HD pathogenesis
(33). Accordingly, Kwidzinski and Bechmann (34) have pro-
posed that neuroinflammation and neurodegeneration are
linked by IFN-g-mediated Indo induction. In a recent
expression study of amyloid b-peptide-stimulated human post-
mortem brain microglia, the INDO protein was found to be
up-regulated identifying a potential new inflammatory
pathway in Alzheimer’s disease (35). The observed increase
in Indo mRNA expression in the YAC128 mice could
suggest, for the first time, a similar involvement of Indo
leading to neuroinflammation described in HD (29).
Expression levels of INDO mRNA in the human post-mortem
brain were also assessed by qRT–PCR; however, this analysis
was not conclusive (poor amplification) due to very low levels
of INDO mRNA in both HD and control caudate RNA
samples. It is known that RNA degradation in autopsy tissue
is more severe in specific subsets of transcripts or restricted
to specific gene families (34), and INDO transcript abundance
may be decreased due to postmortem changes in the brain.
Further analysis of INDO protein in the context of HD is
needed to draw more conclusive results.
AP1S1 is another striatal-enriched gene which is signifi-
cantly down-regulated in both YAC128 striatum and human
HD postmortem caudate. The protein encoded by this gene
is an important subunit of the clathrin adaptor complex
involved in clathrin-coated vesicle transport of endocytosis
and golgi processing. A very recent study of this gene has
described AP1S1 as the gene responsible for MEDNIK syn-
drome (mental retardation, enteropathy, deafness, peripheral
neuropathy, ichthyosis and keratodermia) and demonstrated
a critical role of AP1S1 in development of the skin and
spinal cord (36). Studies of huntingtin’s protein–protein inter-
actions have provided direct links to proteins involved in cel-
lular transport mechanisms, specifically HTT is thought to
play an important role in neuronal vesicular trafficking.
Impairment of this wild-type HTT function by the polygluta-
mine expansion in mutant HTT has been suggested to result
in decreased endocytosis (37,38). These studies provide a
potential link between AP1S1 gene function and HD. The
reduction of AP1S1 mRNA expression would be predicted to
cause vesicle transport defects involving clathrin-dependent
endocytosis and golgi processing. This observation, however,
requires much deeper investigation of the cellular function
of AP1S1 encoded protein and further validation to confirm
its role in neuronal degeneration in HD.
Detailed characterization of these novel candidate
striatal-enriched transcripts will be the focus of this project
in the future. Detailed investigation of alterations in our
three genes at the protein level is currently underway. Modu-
lating the levels of these candidate transcripts will also provide
further information regarding their function in the brain as
well as their involvement in HD pathology.
Our findings demonstrate the potential value of studying
novel striatal-enriched genes to identify transcripts and
pathways dysregulated by the expression of mutant HTT in
the brain. This study identifies new genes involved in biologi-
cal pathways and processes such as trans-golgi network
vesicle transport and trafficking (Ap1s1), tryptophan metab-
olism in the kynurenine pathway (Indo) and inflammatory
response antigens (Cd4) that represent important candidates
for future investigation of HD pathogenesis. Characterization
of novel striatal-specific genes and their expression changes
in HD will help elucidate disease pathways that have impor-
tant roles in the physiological processes and integrity of stria-
tal neurons.
Summary
Through the use of publicly available data sets and experimen-
tal techniques, we have identified candidate genes with altered
expression in the striatum of a murine HD model and in
human HD caudate. The products of these genes may be
involved in pathways that are relevant to HD pathogenesis,
be useful as biomarkers to follow disease progression, and
may be potential new therapeutic targets for the treatment
of HD.
MATERIALS AND METHODS
SAGE data analysis
SAGE libraries (Supplementary Material, Table S1) were gen-
erated by the Mouse Atlas of Gene Expression Project (www.
mouseatlas.org). The DiscoverySpace software application
(http://www.bcgsc.ca/bioinfo/software/discoveryspace/) was
used to compare the striatum library to 18 other brain region
libraries at dpn 84. These libraries were compared with the
striatum library one at a time after tag counts in each library
were normalized to that of the striatum library (total of 18
pairwise comparisons). A ‘P-value score’ for each striatal tag-
sequence was obtained by calculating the sum of
(12P-values) for that tag in all pairwise comparisons
(P-values obtained using Audic Claverie statistics): P-value
score for tag x ¼ S (12P-value).
IF striatum count . any other brain region count then
P ¼ þ P
IF striatum count , any other brain region count then
P ¼ P
Personal communication: This formula has been generated
by Pavle Vrljicak at BC Cancer Agency, Vancouver, BC.
Candidate striatal-specific tags were selected based on the
following selection criteria: (i) more abundant in striatum,
by at least one tag count, compared with 18 other brain
libraries at dpn 84, (ii) P-value score  13.0 at dpn 84
where 216  P-value score  þ17 and (iii) mean ratio
2.5 when all striatum libraries (n ¼ 5) were compared with
18 other libraries at all available time points (total of 40
libraries). Tag to gene mapping was performed using the
mouse Refseq, MGC and Ensembl databases accessible
through DiscoverySpace. Tag position was determined as
a number whose figure represented the location of the NlaIII
site relative to the polyA tail and whose sign represented the
directionality of the tag relative to the gene to which it was
mapped.
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In situ hybridization database
Allen Brain Atlas (AIBS) (http://www.brainatlas.org/AIBS/)
in situ hybridization images provided a visual assessment of
relative abundance of the transcript corresponding to each
SAGE tag mapping to annotated gene. Clearly, only SAGE
tags mapping to known genes could be filtered through this
process. A demonstrated striatal-enriched/specific expression
pattern in the AIBS in situ hybridization database was considered
a necessary criterion in our analysis. SAGE tags corresponding to
unknown regions were not filtered out at this stage.
Animals
Twelve-month-old female YAC128 mice and WT littermates
on FVB/N (Charles River) strain were used in comparison
studies. For SAGE data validation experiments, we used
tissues from 3-month-old WT female mice on FVB/N strain
background. Mice were group-housed with a normal light–
dark cycle and given free access to food and water. Experiments
were carried out in accordance with our institutional animal care
guidelines. All experiments were approved by the University of
British Columbia’s Committee for Animal Care.
Human post-mortem caudate and putamen samples
Supplementary Material, Table S2 provides a summary of
human post-mortem caudate/putamen samples used in our
experiments. These samples comprised a subset of RNAs
described in a previous study [Hodges et al. (8)] extracted
from tissues obtained from the Harvard Brain Tissue Resource
Center.
Quantitative real-time PCR
Mouse experiments. For SAGE validation experiments, RNA
from four brain regions (striatum, cortex, cerebellum and hip-
pocampus) as well as liver and gastrocnemius muscle was pre-
pared from three 3-month-old mice using the RNeasy kit
(Qiagen). Similarly, for transgenic and WT comparison exper-
iments, RNA was extracted from fresh-frozen dissected striata
of 11 wild-type and 8 YAC128 transgenic 12-month-old litter-
mate mice. RNA was also extracted from six 12-month-old
YAC18 animals for YAC18 versus YAC128 comparison exper-
iments. Primers were designed using Primer3 (http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3www.cgiT) and amplicons
spanned introns where possible. Amplicons were between 110
and 150 bp for efficient amplification. Primer efficiencies
were determined using a dilution series of adult striatum
cDNA. Only primer pairs with an efficiency greater than 0.98
were used in subsequent analyses. The primers were also
designed to encompass the SAGE tag (See Supplementary
Material, Table S2 for the list of mouse primers). An ABI
7000 real-time PCR system (Applied Biosystems) and
SYBRw Green Master mix (Qiagen) were used for validations
of the SAGE data. An ABI 7500 real-time PCR system (stan-
dard protocol) and SYBRw Green Master mix (Qiagen) were
used to compare wild-type and YAC128 mRNA. cDNA was
obtained by the reverse transcription (RT) of 1 mg of total
RNA from freshly dissected brain regions using the Quantitect
RT kit (Qiagen). All reactions were carried out in duplicate
using 2 ml of cDNA in each reaction. Duplicates with inconsist-
ent amplification were removed from the analysis. Absolute
quantity of the targets in each sample was calculated based on
the standard curve method and normalized to endogenous
control, b-actin (reverse primer sequence:
50TGTGTTGGCATAGAGGTCTTTACG30; forward primer
sequence:
50CCAGCCTTCCTTCTTGGGTAT30).
Human post-mortem experiments. RNA was extracted from 11
brain samples listed in Supplementary Material, Table S1
using the RNeasy kit (Qiagen). Primers were designed
similar to mouse primers against human genome for human
AP1S1, CD4, INDO and DARPP32. Primer efficiencies were
determined as in mouse experiments. An ABI 7500 real-time
PCR system (Fast protocol) using ABI Fast SYBR Green
Master mix (Applied Biosystems) was used. All reactions
were carried out in duplicates. For the analysis, relative quan-
tity was calculated based on the standard curve method. Sup-
plementary Material, Table S3 contains the human specific
primers designed for qRT–PCR experiments. We analyzed
multiple control genes (GAPDH, b-ACTIN, phosphoglycerate
kinase 1 (PGK1) for normalization of the human qRT–PCR
data. We applied the GeNorm software analysis for calculation
of the most accurate normalization factor for our data measure-
ments (39). The normalization factor (NF) was based on geo-
metric averaging of multiple internal control genes and
calculations were based on the average expression stability
and pairwise variation analysis using the GeNorm-software.
Statistical analysis
In SAGE validation experiments, a one-way ANOVA was per-
formed for determining differences in the relative quantity of
targets of interest between different tissues. Statistical com-
parisons were performed in a pair-wise fashion between stria-
tum and every other tissue. In WT versus transgenic
experiments, a two-tailed Student’s t-test was performed for
determining differences in the mean between the two groups
and Levene’s test to determine equality of variance. Differ-
ences were assumed statistically significant if they reached
the 95% confidence level. All values are represented as
averages with standard error of the mean.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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